BioNxt Solutions (TSE:BNXT) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioNxt Solutions has expanded its patent portfolio by filing new international patents for sublingual drug delivery technologies, targeting autoimmune neurodegenerative diseases like Multiple Sclerosis and Myasthenia Gravis. The company aims to initiate clinical trials for its lead product, BNT23001, in 2025, with plans to develop strategic partnerships to accelerate commercialization.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
